Piper Sandler lowered the firm’s price target on Optinose to $3 from $4 and keeps an Overweight rating on the shares following the company’s Q2 report and 2023 Xhance sales guidance range bump. The firm attributes its lower target to a higher share count.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OPTN: